Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (22,2 Mio. €): European HIV Vaccine Alliance (EHVA): eine EU-Plattform zur Entdeckung und Bewertung neuartiger prophylaktischer und therapeutischer Impfstoffkandidaten Hor01.01.2016 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Text
European HIV Vaccine Alliance (EHVA): eine EU-Plattform zur Entdeckung und Bewertung neuartiger prophylaktischer und therapeutischer Impfstoffkandidaten
Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the European HIV Vaccine Alliance (EHVA) program will develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. The Specific Objectives of the MVP are to build up: 1.Discovery Platform with the goal of generating novel vaccine candidates inducing potent neutralizing and non-neutralizing antibody responses and T-cell responses, 2. Immune Profiling Platform with the goal of ranking novel and existing (benchmark) vaccine candidates on the basis of the immune profile, 3. Data Management/Integration/Down-Selection Platform, with the goal of providing statistical tools for the analysis and interpretation of complex data and algorithms for the efficient selection of vaccines, and 4. Clinical Trials Platform with the goal of accelerating the clinical development of novel vaccines and the early prediction of vaccine failure. EHVA project has developed a global and innovative strategy which includes: a) the multidisciplinary expertise involving immunologists, virologists, structural biology experts, statisticians and computational scientists and clinicians; b) the most innovative technologies to profile immune response and virus reservoir; c) the access to large cohort studies bringing together top European clinical scientists/centres in the fields of prophylactic and therapeutic vaccines, d) the access to a panel of experimental HIV vaccines under clinical development that will be used as benchmark, and e) the liaison to a number of African leading scientists/programs which will foster the testing of future EHVA vaccines through EDCTP
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| 414.974 € | |
| 15.000,00 € | |
| CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS | 0,00 € |
| CHU Hopitaux de Bordeaux | 0,00 € |
| 516.901 € | |
| Commissariat a L Energie Atomique et aux Energies Alternatives | 707.843 € |
| EUROPEAN AIDS TREATMENT GROUP e. V. | 50.000 € |
| 0,00 € | |
| Erasmus Universitair Medisch Centrum Rotterdam | 310.000 € |
| FIT BIOTECH Oy | 965.184 € |
| 0,00 € | |
| 310.879 € | |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | 722.162 € |
| Hospital Clinic de Barcelona | 0,00 € |
| Imperial College of Science Technology and Medicine | 916.601 € |
| Inserm Transfert SA | 580.710 € |
| Institut National de la Sante et de la Recherche Medicale | 2.118.824 € |
| 15.000,00 € | |
| 4.391.787 € | |
| 249.964 € | |
| Istituto Superiore DI Sanita | 537.250 € |
| Janssen Vaccines & Prevention B.V. | 34.845 € |
| Karolinska Institutet | 513.246 € |
| 992.500 € | |
| LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN | 365.000 € |
| 515.000 € | |
| 15.000,00 € | |
| Sanofi Pasteur SA | 50.000 € |
| 0,00 € | |
| Stichting Amsterdam UMC | 0,00 € |
| Stichting Biomedical Primate Research Center | 1.000.018 € |
| 93.749 € | |
| THE General Hospital Corporation | 46.511 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 564.978 € |
| The University of Liverpool | 300.000 € |
| UNIVERSITAET BERN | 0,00 € |
| UNIVERSITAET REGENSBURG | 1.076.175 € |
| UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF | 616.500 € |
| 0,00 € | |
| UNIVERSITE DE LAUSANNE | 0,00 € |
| 24.985 € | |
| Universite Grenoble Alpes | 567.638 € |
| Universite de Bordeaux | 0,00 € |
| Universite de Strasbourg | 0,00 € |
| 2.514.226 € | |
| VACCINE FORMULATION INSTITUTE(CH)Ltd. | 0,00 € |
| Vrije Universiteit Brussel | 75.074 € |
Quelle: https://cordis.europa.eu/project/id/681032
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "Agencia Estatal Consejo Superior de Investigaciones Cientificas - EU-Förderung (22,2 Mio. €): European HIV Vaccine Alliance (EHVA): eine EU-Plattform zur Entdeckung und Bewertung neuartiger prophylaktischer und therapeutischer Impfstoffkandidaten"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
